Why Gold Stocks Edged Higher after Rate Hike
After remaining subdued for the past few months, gold futures last week recorded their highest weekly gain of 2.4% since February 3.
Index & Mutual Funds
Track the hottest index funds and check in on the performance of mutal funds with Market Realist's financial analysts.
How Trump’s Proposed Policies Have Caused Sector Divergence
Despite the stellar run that financials (FAS) have had since the US elections in November 2016, financials are trading at very reasonable levels.
Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters
Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.
Could Novartis’s CTL019 Capture Significant Market Share?
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Short Interest: OFS Stocks with the Lowest Returns in 1Q17
Short interest in Nabors Industries (NBR), as a percentage of its float, rose to 11.5% as of March 31, 2017—compared to 6.5% as of December 30, 2016.
Are Sanofi’s Established Prescription Products Adding Up?
Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.
Inside Sanofi’s Overall Revenue Performance in 2016
Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.
Why Entresto Could Become Key Growth Driver for Novartis in 2017
Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.
Can March’s Manufacturing PMI Boost Germany’s Business Climate?
The Markit Germany manufacturing PMI stood at 58.3 in March 2017 compared to 56.8 in February.
Novartis’s Valuation Compared to Its Peers’
Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.
What Will Drive AstraZeneca’s Oncology Revenues in 2017?
In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.
How Will Competitive Landscape in Media Industry Affect Comcast?
Comcast stated that the key to getting ahead of the competition has been the company’s strategy to offer products based on market segmentation.
Patterson-UTI Energy’s Forecasts for 2017
Patterson-UTI Energy’s (PTEN) operated average US rig count is expected to rise 21.0% in 1Q17 compared to 4Q16.
How the Mobileye Acquisition Could Impact Intel’s Earnings
Intel (INTC) is acquiring Mobileye (MBLY) for a hefty premium compared to MBLY’s earnings.
Why Most Analysts Rate Chevron a ‘Buy’
Analyst ratings for Chevron Chevron (CVX) has been rated by 25 analysts. Of the total, 17 analysts have given “buy” or “strong buy” ratings, eight have given “hold” ratings, and none have given “sell” or “strong sell” ratings on the stock. These ratings have improved from March 2016, when Chevron had fewer “buy” ratings, more […]
Chevron’s Mafumeira Sul Project Kick-Starts Production
In this series, we’ll provide updates on Chevron’s market performance. We’ll examine CVX’s latest stock performance, analyst ratings, dividend yield, PEG (price-to-earnings-to-growth) ratio, beta, short interest position, institutional ownership status, and implied volatility movement.
Why ConocoPhillips Stock Is Outperforming Crude Oil and Peers
In the last two weeks, the stock of ConocoPhillips (COP), a crude oil (USO) and natural gas (UNG) producer, has outperformed crude oil prices.
What Electronic Arts’ Key Metrics Indicate
Revenue from EA’s international markets fell 5.0% YoY (year-over-year) from $622.0 million in fiscal 3Q16 to $588.0 million in fiscal 3Q17.
National Oilwell Varco’s Growth Prospects in 2017
National Oilwell Varco’s (NOV) management expects upstream activity in North America’s shale plays to improve in 2017.
The Outlook for Apple’s Performance in China
Apple’s (AAPL) revenues from Europe rose 3.0% to $10.5 billion, and its revenues from the Asia-Pacific region rose 8.0% to $5.9 billion.
ExxonMobil Focuses on Integrated Growth, Reveals the Path Forward
In its latest analyst meeting, ExxonMobil (XOM) announced that it had plans to concentrate on an integrated earnings model, capturing value at every stage of the energy chain.
Are Rising Chinese Steel Inventories a Risk for Steel Investors?
With higher steel production and subdued demand, one would expect a tsunami of Chinese steel exports, but this wasn’t the case last month. So what did China want with so much steel?
Janet Yellen and the US Dollar Impacted Crude Oil Prices
The US dollar and crude oil (ERY) (ERX) (DIG) (XES) are usually inversely related. A weaker US dollar makes crude oil more affordable for oil importers.
How Flotek Industries Is Valued versus Peer Stocks
Core Laboratories (CLB) is the largest company by market capitalization among our set of select oilfield services and equipment (or OFS) companies…
Growth of AstraZeneca’s Oncology Segment in 2016
The revenues for AstraZeneca’s (AZN) Oncology segment rose ~20% at constant exchange rates in 2016.
Flotek Industries’ Capex: Impact of a Credit Facility Agreement
In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flows trended over the past few quarters.
How the Removal of Dodd-Frank Could Affect Banks
While the Dodd-Frank Act was passed to avoid another financial crisis, it has crippled banks’ profitabilities over the years due to higher capital requirements.
Resilient Global Growth Supports Equities
OppenheimerFunds Leading indicators of the global economy are climbing and that generally bodes well for equities. Previously, we highlight the tight fit between the JP Morgan Global Composite Purchasing Managers’ Index (black line, left axis)—a leading indicator of worldwide business activity—and the year-over-year returns of the MSCI All Country World Index (ACWI) returns since 2000. […]
ON Semiconductor’s Revised Organizational Structure
The Power Solutions Group’s revenues rose 34.3% sequentially to $620.3 million in 4Q16. More than $200 million in revenues came from the Fairchild Semiconductor integration.
U.S. Economic Drag Is Fading, Upside Surprises Are Possible
OppenheimerFunds The U.S. economy was weaker than expected in 2016, the lagged effect of the Fed’s policy mistake in 2015. In our opinion, the worst is now over for the United States, and economic growth should improve in 2017 and could even surprise to the upside with an appropriate fiscal policy mix from the new […]
The Cycle Continues, but the Risks Are Rising
OppenheimerFunds In response to accusations of flip-flopping, John Maynard Keynes purportedly quipped, “When the facts change, I change my mind. What do you do, sir?” With 2017 in full swing, the facts have changed. Since the financial crisis, the global economy has been mired in a slow growth, disinflationary world. We argued that the weak […]
Synergies from the ON–Fairchild Semiconductor Merger
ON Semiconductor (ON) expects the Fairchild Semiconductor merger to bring in annual cost synergies of $225 million by 2019 compared with just $160 million in 2017.
Ron Baron’s Investment Strategy to Beat Inflation in the Long Run
Inflation is expected to reduce the value of assets if the price rise of the asset doesn’t catch up with inflation. Core inflation in the United States is growing at a rate of ~2%.
These Prescription Products Matter to Sanofi’s Growth
Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.
What Were GoPro’s Metrics in 4Q16?
According to NPD Group’s retail tracking service, GoPro (GPRO) accounted for three out of the top five products—including the top two positions—on a unit basis in the US Digital Imaging Product segment for 4Q16.
Novartis’s Valuation after the 4Q16 Results
On January 31, 2017, Novartis was trading at a forward PE multiple of ~15.2x. Based on its last-five-year multiple range, this is neither high nor low.
Altria Stock Rose on Strong 4Q16 Earnings
Altria Group (MO) announced its 4Q16 earnings on February 1, 2017. The company posted net revenue of $4.7 billion and EPS (earnings per share) of $5.27.
Inside Novartis’s Generics Performance in 4Q16
Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.
Will Philip Morris’s 4Q16 Earnings Results Boost Its Stock Price?
Philip Morris International (PM), a US-based tobacco company, is set to announce its 4Q16 earnings on February 2, 2017, before the market opens.
What’s the Correlation Between XOM and WTI?
Integrated energy companies such as ExxonMobil are affected to varying degrees by volatility in crude oil prices. XOM’s correlation coefficient with WTI stands at 0.56.
Analysts Expect Negative Growth for Novartis in 4Q16
Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.
What Does the Rising US Consumer Sentiment Index Mean for the Economy?
The US Consumer Sentiment Index improved in January 2017. It stood at 98.1 in January 2017 compared to 98.2 in December 2016.
How Did Novartis’s Innovative Medicines Segment Perform?
The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.
What Could Impact Chinese Steel Prices in 2017?
Since China is the world’s largest steel producer and exporter, it’s important for investors to keep track of Chinese steel prices.
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016
On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.
The REIT Advantage: High Return, Low Correlation
RETURNS AND RISKS OF REITS REIT and property stock performance has been relatively strong over the long term, especially when compared with traditional bond and equity indices. Since 1992, the Dow Jones Global Ex-U.S. Select RESI has had an average total return close to 9%, while the Dow Jones U.S. Select REIT Index has had […]
The Evolution of the REIT
The Evolution of REITs The basic concept of REITs originated with the business trusts that were formed in Massachusetts in the mid-19th century, when the wealth created by the industrial revolution led to a demand for real estate investment. The first REIT was set up in 1961, but it took several decades before REITs were […]
A Close Look at Trivago’s Business Model
Trivago combines hotel content from various sources on its platform. These hotels are then displayed to users based on their search criteria.
Teva’s Research Pipeline to Culminate in Many New Drug Launches?
Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.
Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’
In his November Insights newsletter, Richard Bernstein stated, “It is incredible that investors have basically been wallflowers during the second longest bull market of the post-war period.”